Tier 2 — strong

Oral sodium hyaluronate improves skin hydration, barrier function and signs of aging: a randomized, double-blind, placebo-controlled trial in 150 healthy adults

Iva Dolečková, Pavel Kušnierik, Vratislav Berka, Matěj Šimek, Ilona Matějková, Filip Prokopec, Petra Ovesná
Scientific Reports 2025 16:2941

Bibliography

PubMed
PMID 41422283
PubMed Central
PMC12827323
DOI
10.1038/s41598-025-32758-5
Trial registry
View on ClinicalTrials.gov Registered trial — results not yet published in a peer-reviewed journal.
Funding
Funded by Contipro a.s.
Competing interests
Six of seven authors were employees of Contipro a.s.; Petra Ovesná declared no conflict of interest.

Study snapshot

DesignRandomized, double-blind, placebo-controlled, parallel-group clinical trial
Model150 healthy Caucasian adults
Samplen=150 randomized
InterventionSodium hyaluronate (1.8 MDa) at 60 mg/day or 120 mg/day versus placebo
Duration12 weeks
EndpointsFacial skin hydration; Transepidermal water loss; Skin elasticity; Periorbital wrinkle depth; Sebum; Epidermal thickness; Dermal density; Natural moisturizing factor

What the study showed, in plain terms

This randomized trial assigned 150 healthy adults to 60 mg/day, 120 mg/day or placebo for 12 weeks using 1.8 MDa sodium hyaluronate.

The 120 mg dose significantly improved hydration and elasticity and reduced transepidermal water loss, sebum and periorbital wrinkle depth versus placebo. The 60 mg dose produced similar but generally smaller effects.

It is the largest modern oral-HA skin RCT in this Data Center, but it was funded by Contipro and six authors were company employees.

Key findings

  • 120 mg/day improved hydration and elasticity and reduced TEWL and periorbital wrinkle depth versus placebo.
  • 60 mg/day showed similar but more modest effects.
  • The study also reported improvements in epidermal thickness, dermal density and natural moisturizing factor at 120 mg/day.

What this study can and cannot tell us

  • Industry-funded, with six authors employed by the manufacturer.
  • Single-center trial in a Caucasian population limits generalizability.
  • ClinicalTrials.gov registration was retrospective, although the EFSA registry entry was prospective.

Citation network

Articles citing this research paper

10 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology